Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells

Area of Science:

• Immunology
• Cancer Research
• Cell Biology

Background:

• Dendritic cells (DCs) have specialized functions, with plasmacytoid DCs (pDCs) and CD8α DCs potentially influencing antitumor CD8 T cell responses.
• The precise roles and necessity of these DC subsets in initiating antitumor immunity remain incompletely understood.

Purpose of the Study:

• To investigate the importance of pDC and CD8α DC subsets in the immunotherapy of metastatic renal cell carcinoma.
• To elucidate the mechanisms by which these DC subsets contribute to antitumor immune responses.

Main Methods:

• Utilized an orthotopic model of metastatic renal cell carcinoma in BALB/c mice.
• Administered immunotherapy combining recombinant adenovirus encoding tumor necrosis factor-related apoptosis-inducing ligand (Ad5-TRAIL) with CpG oligodeoxynucleotides (CpG).
• Examined the impact of pDC depletion (anti-PDCA1 mAb) and CD8α DC deficiency (Batf3(-/-) mice) on therapeutic efficacy and immune cell function.

Main Results:

• Ad5-TRAIL/CpG immunotherapy eradicated tumors and prolonged survival in wild-type mice.
• Mice deficient in pDC or CD8α DC exhibited uncontrolled tumor growth and mortality post-therapy.
• Therapeutic failure in deficient mice was associated with altered DC activation, reduced type I IFN-stimulated genes, and decreased IL-15/IL-15R complex production.
• Reduced effector CD8 T cell infiltration was observed in the primary tumor site of deficient mice compared to wild-type mice.

Conclusions:

• pDC and CD8α DC subsets play independent yet complementary roles essential for initiating an effective antitumor immune response.
• These DC subsets are necessary for the efficacy of Ad5-TRAIL/CpG immunotherapy in clearing primary and metastatic tumors.